No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

TUESDAY, Jan. 7, 2025 (HealthDay News) -- For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...